Excision BioTherapeutics Inc. is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. We develop gene editing medicines that eradicate or disrupt viral genes in human patients.

Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world. 

The company was founded in 2015 and has produced a considerable intellectual property portfolio and therapeutic pipeline covering the use of CRISPR gene editing-based medicines.